DAPAGLIFLOZIN EXPERIENCE AS ADDED TO TRIPLE THERAPY FOR THE TREATMENT OF UNCONTROLLED TYPE 2 DIABETES MELLITUS PATIENTS IN A CENTRE OF HIGH COMPLEXITY, CALI-COLOMBIA

被引：0
|
作者：
Buitrago Gomez, N. [1 ]
Bedoya, V. [1 ]
Osorio, L. [2 ]
Salgado, C. [1 ]
Carvajal Ortiz, R. [1 ]
Abreu Lomba, A. [1 ]
机构：
[1] Univ Libre Cali, Internal Med, Cali, Colombia
[2] Univ Santiago, Cali, Colombia
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2020年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
447
引用
收藏
页码：A181 / A181
页数：1
相关论文
共 50 条
  • [1] DAPAGLIFLOZIN EXPERIENCE AS ADDED TO TRIPLE THERAPY FOR THE TREATMENT OF UNCONTROLLED TYPE 2 DIABETES MELLITUS PATIENTS IN A CENTRE OF HIGH COMPLEXITY, CALI-COLOMBIA
    Buitrago Gomez, N.
    Bedoya, V.
    Abreu Lomba, A.
    Munoz, J.
    Osorio, L.
    Salgado, C.
    Carvajal Ortiz, R.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A181 - A182
  • [2] Effectiveness of triple therapy with dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity, Cali-Colombia
    Bedoya Joaqui, Vanessa
    Buitrago Gomez, Nathalia
    Carvajal Ortiz, Reinaldo
    Osorio Toro, Luis Miguel
    Munoz Lombo, Jenny Patricia
    Salgado Cifuentes, Carlos Alberto
    Morales Garcia, Monica Andrea
    Abreu Lomba, Alin
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2021, 65 (01): : 49 - 59
  • [3] Effect of Dapagliflozin on renal protection in patients with uncontrolled type 2 diabetes mellitus
    张德园
    ChinaMedicalAbstracts(InternalMedicine), 2020, 37 (01) : 21 - 22
  • [4] Experience with Dapagliflozin in Germany Triple Oral Therapy in Type 2 Diabetes
    不详
    DIABETES STOFFWECHSEL UND HERZ, 2015, 24 (06): : 403 - 405
  • [5] Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes
    Handelsman, Yehuda
    Mathieu, Chantal
    Del Prato, Stefano
    Johnsson, Eva
    Kurlyandskaya, Raisa
    Iqbal, Nayyar
    Garcia-Sanchez, Ricardo
    Rosenstock, Julio
    DIABETES OBESITY & METABOLISM, 2019, 21 (04): : 883 - 892
  • [6] Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus
    Hector E. Tamez
    Alejandra L. Tamez
    Lucas A. Garza
    Mayra I. Hernandez
    Ana C. Polanco
    Journal of Diabetes & Metabolic Disorders, 14 (1):
  • [7] Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus
    Tamez, Hector E.
    Tamez, Alejandra L.
    Garza, Lucas A.
    Hernandez, Mayra I.
    Polanco, Ana C.
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2015, 14
  • [8] Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes
    Rosenstock, Julio
    Perl, Shira
    Johnsson, Eva
    Garcia-Sanchez, Ricardo
    Jacob, Stephan
    DIABETES OBESITY & METABOLISM, 2019, 21 (09): : 2152 - 2162
  • [9] Perception of insulin therapy in uncontrolled patients with type 2 diabetes mellitus
    Leyva Jimenez, Rafael
    Hernandez Zambrano, Gustavo
    Ibarra Maldonado, Silvia
    Ibarra Ramirez, Carlos Tomas
    ATENCION PRIMARIA, 2016, 48 (08): : 543 - 549
  • [10] Changes in lipid profiles of patients with type 2 diabetes mellitus on dapagliflozin therapy
    Hardy, E.
    Ptaszynska, A.
    de Bruin, T. W. A.
    Johnsson, E.
    Parikh, S. J.
    List, J. F.
    DIABETOLOGIA, 2013, 56 : S379 - S379
12345